Cutaneous Mastocytosis
Overview of Cutaneous Mastocytosis
Cutaneous mastocytosis is a condition characterized by fixed pigmented skin spots that become symptomatic when gently rubbed or by other triggers such as heat. The pigmented spots are due to an accumulation of abnormal mast cells in the skin. Mast cells are a type of immune cell that identifies danger and protects the body. They are normally in the body’s environmental barriers like the skin, lungs and digestive tract where they can identify danger early and alert the body. While all humans have mast cells in their skin, patients with cutaneous mastocytosis have a much higher number of mast cells in the skin that are abnormal.
When mast cells activate or “degranulate” they release stored chemicals like histamine, leukotrienes and prostaglandins. These chemicals cause symptoms in patients with cutaneous mastocytosis such as hives, blistering, itching, redness and flushing. Because mast cells also cause symptoms in more common allergic diseases, these symptoms overlap with conditions like hives, angioedema or eczema. The fixed spots or pigmented lesions of cutaneous mastocytosis contain not only abnormal mast cells, but also pigment-bearing cells (melanocytes) causing a characteristic reddish-brown appearance.
Cutaneous mastocytosis affects both children and adults, but the disease course differs by age. In children, the disease is confined to the skin and resolves over time. Most children with cutaneous mastocytosis will not have the disease by adulthood. In contrast, adult-onset cutaneous mastocytosis or “mastocytosis-in-the-skin” (beginning after age 16) is nearly always associated with systemic mastocytosis. Unlike cutaneous mastocytosis, systemic mastocytosis is a lifelong disease and is associated with symptoms across multiple parts of the body in addition to the skin.
What are the Symptoms & Diagnosis of Cutaneous Mastocytosis?
Cutaneous mastocytosis most often appears as persistent tan, brown or reddish spots or bumps on the skin. Some patients have a single raised patch, while others have more widespread skin changes. The affected areas may become itchy, red or swollen when rubbed or scratched – a reaction known as the Darier sign. Blistering can also occur, particularly in infants and young children. Heat, friction and other individual triggers may cause symptoms to flare. Chemicals released by mast cells can also cause flushing, abdominal discomfort or diarrhea, even when mastocytosis is limited to the skin. Anaphylaxis, a severe reaction that may include difficulty breathing or fainting, can occur and requires immediate emergency treatment.
Diagnosis begins with a medical history and skin examination by an allergist / immunologist or dermatologist. In some cases, a small skin sample, called a biopsy, may be needed to confirm the diagnosis, but this is not needed to establish the diagnosis. Blood tests may include a baseline tryptase level, which measures a chemical released by a mast cell, and helps guide further evaluation. A tryptase result alone cannot confirm or rule out systemic mastocytosis. Most children have disease limited to the skin and do not need a bone marrow biopsy unless concerning symptoms, examination findings or laboratory results suggest otherwise. Adults with mastocytosis skin lesions need an evaluation for systemic mastocytosis, which involves organs beyond the skin and requires a bone marrow biopsy for final diagnosis.
How do you Manage Cutaneous Mastocytosis?
Cutaneous mastocytosis in the absence of systemic mastocytosis currently has no FDA-approved therapy. Management is symptom-directed, aimed at controlling mast cell mediator release and its consequences. Patients and caregivers should be instructed to identify and avoid triggers, which vary from patient to patient. Medications typically start with second-generation H1 antihistamines, titrated as needed to control pruritus, flushing, hives and blistering. H2 antagonists such as famotidine, cromolyn sodium and leukotriene receptor antagonists may be added as second-line options. Topical corticosteroids may help localized lesions, but short courses of systemic corticosteroids are typically reserved for severe symptoms. Phototherapy and omalizumab have been used for refractory symptoms in some patients.
Patients and caregivers should be prepared to treat anaphylaxis since anaphylaxis can happen in adult and pediatric patients with systemic mastocytosis with skin involvement as well as occasionally in children with cutaneous mastocytosis. Patients should have a written anaphylaxis action plan, and epinephrine should be available to patients with a prior history of anaphylaxis or other risk factors like an elevated baseline serum tryptase, diffuse cutaneous disease or venom allergy. While most pediatric patients with cutaneous mastocytosis will have disease remission by adolescence, adult-onset disease is nearly always associated with systemic mastocytosis and warrants evaluation with a serum tryptase and KIT D816V testing. Definitive diagnosis requires a bone marrow biopsy. KIT-directed tyrosine kinase inhibitors are approved for systemic mastocytosis, but not for cutaneous mastocytosis without systemic involvement.
The Value of the Allergy / Immunology Specialist
The AAAAI's Find an Allergist / Immunologist service is a trusted resource to help you find a specialist close to home.
Matthew P. Giannetti, MD
Brigham and Women’s Hospital, Division of Allergy and Clinical Immunology
Harvard Medical School
Jeremy C. McMurray, MD
Walter Reed National Military Medical Center, Department of Allergy and Immunology
Uniformed Services University, Department of Pediatrics
Brandon J. Schornack, DO
Walter Reed National Military Medical Center, Department of Allergy and Immunology
Uniformed Services University, Department of Pediatrics
10/14/2026